Stately Bio

Founded in 2022 in Palo Alto, US, Stately Bio focuses on regenerative medicine with a unique machine learning cell imaging platform. The firm's operations have expanded to include significant partnerships with top-tier research institutions and biotechnology companies globally. The founder, whose background includes significant experience in the biotech sector, has a vision for advancing cell therapy innovations.Stately Bio specializes in pioneering regenerative medicine through its advanced machine learning (ML) cell imaging platform. The company’s core products leverage patented ML technology to perform live-cell, label-free imaging, enabling the measurement of cell identity, behavior, and maturation without compromising cell viability. These capabilities serve the end use cases of enhancing the discovery and development of novel stem cell-derived therapies, addressing significant challenges in cell therapy innovation. Stately Bio collaborates with leading institutions and companies within the regenerative medicine sector, targeting markets globally, including North America and Europe.Stately Bio operates on a revenue model that incorporates partnerships and direct collaborations with top-tier research institutions and biotechnology firms. The business transactions primarily involve service agreements wherein clients utilize Stately Bio's proprietary ML imaging technology for their cell therapy research and development projects. These collaborations are structured as contract-based arrangements, often featuring tiered pricing depending on the scope and duration of the partnership. The company is set to expand its operations into new markets, specifically targeting Europe and Asia by the end of 2026. Additionally, Stately Bio is developing new products that enhance its existing ML imaging technology, with plans for a product launch expected in late 2025.

1. Seed

   May 1, 2025

   Amount

   $12M

   Investors

   Locked